173 related articles for article (PubMed ID: 21238586)
1. Ultrasound-mediated destabilization and drug release from liposomes comprising dioleoylphosphatidylethanolamine.
Evjen TJ; Nilssen EA; Barnert S; Schubert R; Brandl M; Fossheim SL
Eur J Pharm Sci; 2011 Mar; 42(4):380-6. PubMed ID: 21238586
[TBL] [Abstract][Full Text] [Related]
2. Lipid membrane composition influences drug release from dioleoylphosphatidylethanolamine-based liposomes on exposure to ultrasound.
Evjen TJ; Nilssen EA; Fowler RA; Røgnvaldsson S; Brandl M; Fossheim SL
Int J Pharm; 2011 Mar; 406(1-2):114-6. PubMed ID: 21185927
[TBL] [Abstract][Full Text] [Related]
3. Distearoylphosphatidylethanolamine-based liposomes for ultrasound-mediated drug delivery.
Evjen TJ; Nilssen EA; Rögnvaldsson S; Brandl M; Fossheim SL
Eur J Pharm Biopharm; 2010 Aug; 75(3):327-33. PubMed ID: 20434558
[TBL] [Abstract][Full Text] [Related]
4. Sonosensitive dioleoylphosphatidylethanolamine-containing liposomes with prolonged blood circulation time of doxorubicin.
Evjen TJ; Hagtvet E; Nilssen EA; Brandl M; Fossheim SL
Eur J Pharm Sci; 2011 Jul; 43(4):318-24. PubMed ID: 21620968
[TBL] [Abstract][Full Text] [Related]
5. Physicochemical characterization of liposomes after ultrasound exposure - mechanisms of drug release.
Evjen TJ; Hupfeld S; Barnert S; Fossheim S; Schubert R; Brandl M
J Pharm Biomed Anal; 2013 May; 78-79():118-22. PubMed ID: 23474811
[TBL] [Abstract][Full Text] [Related]
6. Development of pH-sensitive liposomes that efficiently retain encapsulated doxorubicin (DXR) in blood.
Ishida T; Okada Y; Kobayashi T; Kiwada H
Int J Pharm; 2006 Feb; 309(1-2):94-100. PubMed ID: 16364578
[TBL] [Abstract][Full Text] [Related]
7. Optimization of a novel and improved thermosensitive liposome formulated with DPPC and a Brij surfactant using a robust in vitro system.
Tagami T; Ernsting MJ; Li SD
J Control Release; 2011 Sep; 154(3):290-7. PubMed ID: 21640149
[TBL] [Abstract][Full Text] [Related]
8. Targeted temperature sensitive magnetic liposomes for thermo-chemotherapy.
Pradhan P; Giri J; Rieken F; Koch C; Mykhaylyk O; Döblinger M; Banerjee R; Bahadur D; Plank C
J Control Release; 2010 Feb; 142(1):108-21. PubMed ID: 19819275
[TBL] [Abstract][Full Text] [Related]
9. Ultrasound, liposomes, and drug delivery: principles for using ultrasound to control the release of drugs from liposomes.
Schroeder A; Kost J; Barenholz Y
Chem Phys Lipids; 2009 Nov; 162(1-2):1-16. PubMed ID: 19703435
[TBL] [Abstract][Full Text] [Related]
10. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial?
Hong RL; Huang CJ; Tseng YL; Pang VF; Chen ST; Liu JJ; Chang FH
Clin Cancer Res; 1999 Nov; 5(11):3645-52. PubMed ID: 10589782
[TBL] [Abstract][Full Text] [Related]
11. In vivo monitoring of liposomal release in tumours following ultrasound stimulation.
Evjen TJ; Hagtvet E; Moussatov A; Røgnvaldsson S; Mestas JL; Fowler RA; Lafon C; Nilssen EA
Eur J Pharm Biopharm; 2013 Aug; 84(3):526-31. PubMed ID: 23274944
[TBL] [Abstract][Full Text] [Related]
12. Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells.
Ishida T; Kirchmeier MJ; Moase EH; Zalipsky S; Allen TM
Biochim Biophys Acta; 2001 Dec; 1515(2):144-58. PubMed ID: 11718670
[TBL] [Abstract][Full Text] [Related]
13. Flow cytometric analysis of supravesicular structures in doxorubicin-containing pegylated liposomes.
Milosevits G; Rozsnyay Z; Kozma GT; Milosevits J; Tömöry G; Robotka H; Rosivall L; Szebeni J
Chem Phys Lipids; 2012 May; 165(4):482-7. PubMed ID: 22206709
[TBL] [Abstract][Full Text] [Related]
14. Encapsulation of doxorubicin into thermosensitive liposomes via complexation with the transition metal manganese.
Chiu GN; Abraham SA; Ickenstein LM; Ng R; Karlsson G; Edwards K; Wasan EK; Bally MB
J Control Release; 2005 May; 104(2):271-88. PubMed ID: 15907579
[TBL] [Abstract][Full Text] [Related]
15. New doxorubicin-loaded phospholipid microbubbles for targeted tumor therapy: Part I--Formulation development and in-vitro characterization.
Tinkov S; Winter G; Coester C; Bekeredjian R
J Control Release; 2010 Apr; 143(1):143-50. PubMed ID: 20060861
[TBL] [Abstract][Full Text] [Related]
16. The liposomal formulation of doxorubicin.
Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
[TBL] [Abstract][Full Text] [Related]
17. A synthetic peptide mediated active targeting of cisplatin liposomes to Tie2 expressing cells.
Mai J; Song S; Rui M; Liu D; Ding Q; Peng J; Xu Y
J Control Release; 2009 Nov; 139(3):174-81. PubMed ID: 19576253
[TBL] [Abstract][Full Text] [Related]
18. Vascular targeting of doxorubicin using cationic liposomes.
Wu J; Lee A; Lu Y; Lee RJ
Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
[TBL] [Abstract][Full Text] [Related]
19. Cationic liposome (DC-Chol/DOPE=1:2) and a modified ethanol injection method to prepare liposomes, increased gene expression.
Maitani Y; Igarashi S; Sato M; Hattori Y
Int J Pharm; 2007 Sep; 342(1-2):33-9. PubMed ID: 17566677
[TBL] [Abstract][Full Text] [Related]
20. Enzyme-induced shedding of a poly(amino acid)-coating triggers contents release from dioleoyl phosphatidylethanolamine liposomes.
Romberg B; Flesch FM; Hennink WE; Storm G
Int J Pharm; 2008 May; 355(1-2):108-13. PubMed ID: 18206323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
